Dimensional Fund Advisors LP trimmed its position in Xencor, Inc. (NASDAQ:XNCR) by 7.9% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 264,259 shares of the biopharmaceutical company’s stock after selling 22,635 shares during the quarter. Dimensional Fund Advisors LP owned 0.57% of Xencor worth $5,579,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. SG Americas Securities LLC grew its holdings in shares of Xencor by 62.6% during the 2nd quarter. SG Americas Securities LLC now owns 8,447 shares of the biopharmaceutical company’s stock worth $178,000 after purchasing an additional 3,252 shares in the last quarter. Legal & General Group Plc grew its holdings in shares of Xencor by 4.5% during the 2nd quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 385 shares in the last quarter. Citadel Advisors LLC acquired a new stake in shares of Xencor during the 2nd quarter worth $224,000. Airain ltd grew its holdings in shares of Xencor by 49.9% during the 2nd quarter. Airain ltd now owns 13,360 shares of the biopharmaceutical company’s stock worth $282,000 after purchasing an additional 4,447 shares in the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of Xencor by 144.4% during the 1st quarter. Bank of America Corp DE now owns 16,199 shares of the biopharmaceutical company’s stock worth $387,000 after purchasing an additional 9,572 shares in the last quarter. 76.97% of the stock is currently owned by institutional investors.

Several analysts have recently issued reports on the company. Canaccord Genuity reissued a “buy” rating and set a $36.00 target price on shares of Xencor in a report on Tuesday, August 8th. Zacks Investment Research lowered Xencor from a “hold” rating to a “sell” rating in a report on Saturday, November 11th. ValuEngine raised Xencor from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Piper Jaffray Companies reissued a “buy” rating and set a $35.00 target price on shares of Xencor in a report on Sunday, November 12th. Finally, BidaskClub lowered Xencor from a “hold” rating to a “sell” rating in a report on Monday, August 14th. Three analysts have rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $30.25.

In other news, major shareholder John S. Stafford III bought 150,000 shares of the company’s stock in a transaction on Friday, October 27th. The stock was purchased at an average cost of $19.81 per share, for a total transaction of $2,971,500.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder John S. Stafford III bought 50,000 shares of the company’s stock in a transaction on Thursday, November 2nd. The stock was purchased at an average price of $19.58 per share, with a total value of $979,000.00. The disclosure for this purchase can be found here. Insiders purchased 242,382 shares of company stock worth $4,795,353 over the last ninety days. 4.14% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another domain, it was copied illegally and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.watchlistnews.com/dimensional-fund-advisors-lp-decreases-holdings-in-xencor-inc-xncr/1719057.html.

Shares of Xencor, Inc. (NASDAQ XNCR) opened at $21.66 on Wednesday. Xencor, Inc. has a 12 month low of $18.55 and a 12 month high of $29.38.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor, Inc. (NASDAQ:XNCR).

Institutional Ownership by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.